WLCC2015
TARGET AUDIENCE
This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer. OVERVIEW OF ACTIVITY This unique educational activity delivers highly applicable current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
A William Blackstock, MD No real or apparent conflicts of interest to disclose. Julie R Brahmer, MD Advisory Committee: Bristol-Myers Squibb Company, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Paid Research: AstraZeneca Pharmaceuticals LP; Uncompensated Research: Bristol-Myers Squibb Company. David E Gerber, MD Advisory Committee: Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Contracted Research: ArQule Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Peregrine Pharmaceuticals Inc. Ramaswamy Govindan, MD Consulting Agreements: GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Pfizer Inc. Roy S Herbst, MD, PhD Consulting Agreements: Genentech BioOncology, Lilly, Merck. Leora Horn, MD, MSc Advisory Committee: Bristol-Myers Squibb Company, Clovis Oncology, Helix BioPharma Corp, Puma Biotechnology Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Merck; Contracted Research: Astellas Scientific and Medical Affairs Inc; Honoraria: Boehringer Ingelheim Pharmaceuticals Inc. Mark G Kris, MD Advisory Committee: Daiichi Sankyo Inc; Consulting Agreements: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology; Contracted Research: Pfizer Inc, Puma Biotechnology Inc; Other Remunerated Activities: Roche Laboratories Inc. Rogerio C Lilenbaum, MD Advisory Committee: Celgene Corporation, Genentech BioOncology. Joel W Neal, MD, PhD Contracted Research: ArQule Inc, Genentech BioOncology, Merck. Harvey I Pass, MD Contracted Research: Genzyme Corporation. Charles M Rudin, MD, PhD Consulting Agreements: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline, Merck. Mark A Socinski, MD Advisory Committee: Bristol-Myers Squibb Company, Lilly, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly, Pfizer Inc, Takeda Oncology; Speakers Bureau: Celgene Corporation, Genentech BioOncology. Everett E Vokes, MD Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, GeneCentric Diagnostics Inc, Genentech BioOncology, Merck, Synta Pharmaceuticals Corp, VentiRx Pharmaceuticals Inc. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Foundation Medicine, Genentech BioOncology, Lilly, Merck and Novartis Pharmaceuticals Corporation. Hardware/Software Requirements: Last review date: June 2015 |